Medicare Enrolled

Dr. Kartik Konduri, MD

Hematology & Oncology · Dallas, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Consulting-driven
3410 WORTH ST, Dallas, TX 75246
2143701000
In practice since 2006 (19 years)
NPI: 1417995499 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Konduri from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Konduri? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Konduri

Dr. Kartik Konduri is a hematology & oncology in Dallas, TX, with 19 years in practice. Based on federal Medicare data, Dr. Konduri performed 96,810 Medicare services across 3,286 unique beneficiaries.

Between the years covered by Open Payments, Dr. Konduri received a total of $183,738 from 25 pharmaceutical and/or device companies across 160 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Konduri is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 8% volume in TX$ $183,738 industry payments

Medicare Practice Summary

Medicare Utilization ↗
96,810
Medicare services
Top 8% in TX for hematology & oncology
3,286
Unique beneficiaries
$16
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,095 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Pembrolizumab injection (Keytruda)23,300$43$137
Anti-nausea injection (fosaprepitant)19,350$0$5
Paclitaxel chemotherapy injection11,864$0$8
Contrast dye for imaging (iodine-based)10,595$0$3
Iron infusion (Feraheme)8,670$0$5
Daratumumab injection (Darzalex)4,680$38$126
Dexamethasone injection (steroid)2,985$0$1
Injection, docetaxel, 1 mg2,226$0$66
Anti-nausea injection (Aloxi/palonosetron)1,801$1$115
Denosumab injection (Prolia/Xgeva)1,560$19$66
Injection, granisetron hydrochloride, 100 mcg1,010$0$24
Comprehensive metabolic blood panel829$10$64
Complete blood count (CBC) with differential813$8$36
Blood draw (venipuncture)801$8$20
Office visit, established patient (30-39 min)694$97$368
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less608$23$157
Administration of chemotherapy into vein, 1 hour or less446$104$707
Injection, leucovorin calcium, per 50 mg386$3$25
Injection, carboplatin, 50 mg385$2$300
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg380$3$373
Injection of additional new drug or substance into vein363$12$108
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg324$82$1,348
Injection, fluorouracil, 500 mg273$2$13
Office visit, established patient (20-29 min)237$68$250
Injection, magnesium sulfate, per 500 mg180$1$6
Injection, diphenhydramine hcl, up to 50 mg154$1$7
Injection, zoledronic acid, 1 mg153$6$431
Administration of additional new drug or substance into vein, 1 hour or less127$51$344
Injection, cisplatin, powder or solution, 10 mg127$2$94
Hospital follow-up visit, moderate complexity110$62$247
Ct scan of chest with contrast102$53$821
Unclassified drugs101$1$8
Administration of chemotherapy into vein, each additional hour93$22$161
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less91$50$313
CT scan of abdomen and pelvis with contrast85$179$1,067
Infusion, normal saline solution , 1000 cc81$2$19
Drug injection, under skin or into muscle78$11$96
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle70$57$211
Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion54$16$94
CT scan of chest, without contrast52$61$686
Reticulated (young) platelet measurement44$31$143
Infusion into a vein for hydration, each additional hour44$10$75
Hospital follow-up visit, low complexity40$39$135
Administration of chemotherapy into vein using push technique38$81$500
Office visit, established patient, complex (40-54 min)38$140$496
Administration of additional new drug or substance into vein using push technique33$44$289
Microscopic examination for white blood cells with manual cell count31$4$22
Complete blood count (CBC), automated31$6$34
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour30$16$100
Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l28$133$500
Nuclear medicine study from skull base to mid-thigh with ct scan27$1,187$4,802
Application of on-body injector for under skin injection27$15$96
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries26$89$657
Irrigation of implanted venous access drug delivery device23$18$114
Ct scan of soft tissue of neck with contrast21$63$658
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg20$1$17
New patient office visit (45-59 min)19$132$565
Blood creatinine level15$5$31
Basic metabolic blood panel14$8$49
Urinalysis with microscopic exam12$3$28
Office visit, established patient (10-19 min)11$41$150
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
9.9% high complexity
85.9% medium
4.2% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$183,738
Total received (2018-2024)
Avg $26,248/year across 7 years
Top 4% in TX for hematology & oncology
25
Companies
160
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$96,636 (52.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$86,948 (47.3%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$154 (0.1%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$21,537
2023
$30,831
2022
$52,530
2021
$49,010
2020
$10,605
2019
$40
2018
$19,184

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$49,704
E.R. Squibb & Sons, L.L.C.
$20,012
EMD Serono, Inc.
$18,108
Amgen Inc.
$15,752
Takeda Pharmaceuticals U.S.A., Inc.
$13,139
JAZZ PHARMACEUTICALS INC.
$10,904
Mirati Therapeutics, Inc.
$8,414
Janssen Biotech, Inc.
$7,837
Daiichi Sankyo Inc.
$7,498
Boehringer Ingelheim Pharmaceuticals, Inc.
$6,696
Novocure Inc.
$5,722
Regeneron Healthcare Solutions, Inc.
$2,801
Bayer HealthCare Pharmaceuticals Inc.
$2,750
Lilly USA, LLC
$2,400
Blueprint Medicines Corporation
$2,240
Regeneron Pharmaceuticals, Inc.
$2,069
Eli Lilly and Company
$1,875
Janssen Scientific Affairs, LLC
$1,828
ABBVIE INC.
$1,814
PFIZER INC.
$1,441
G1 Therapeutics, Inc.
$634
Genentech USA, Inc.
$40
Novartis Pharmaceuticals Corporation
$28
Merck Sharp & Dohme LLC
$22
Gilead Sciences, Inc.
$12
Top 3 companies account for 47.8% of total payments
Associated products mentioned in payments ›
ALUNBRIG · Alecensa · BOSULIF · COSELA · EPKINLY · EXKIVITY · GILOTRIF · IMDELLTRA (AMG 757) · IMFINZI · KEYTRUDA · KRAZATI · LIBTAYO · LORBRENA · LUMAKRAS · NovoTTF-100L · OPDIVO · RYBREVANT · TABRECTA · TAGRISSO · Tepmetko · Tepotinib · Vitrakvi · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (53%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers. Total industry engagement is in the top 4% for hematology & oncology in TX.

Equivalent to $190 per 100 Medicare services performed
Looking for a hematology & oncology in Dallas?
Compare hematology & oncologys in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncologys nearby

Geographic Context

Hematology & Oncologys within 10 mi
129
Per 100K population
5.0
County median income
$74,149
Nearest hospital
BAYLOR UNIVERSITY MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Konduri is a mixed practice specialist, with above-average Medicare volume (top 8% in TX), and high industry engagement (consulting-driven, top 4%), with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Konduri experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Konduri performed 23,300 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Konduri receive payments from pharmaceutical companies?
Yes. Dr. Konduri received a total of $183,738 from 25 companies across 160 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Konduri's costs compare to other hematology & oncologys in Dallas?
Dr. Konduri's average Medicare payment per service is $16. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Konduri) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →